Bristol-Myers Squibb Company announced Friday that the China Food and Drug Administration (CFDA) has approved a direct-acting antiviral regimen comprised of Daklinza ® (daclatasvir) and Sunvepra ®(asunaprevir),...
The U.S. Food and Drug Administration today approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus (HCV) genotype 3 infections. Daklinza is the first drug that has demonstrated...
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.